Skip to Content

Ranibizumab ophthalmic Side Effects

In Summary

Commonly reported side effects of ranibizumab ophthalmic include: cataract, increased intraocular pressure, and intraocular inflammation. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to ranibizumab ophthalmic: intraocular solution

As well as its needed effects, ranibizumab ophthalmic may cause unwanted side effects that require medical attention.

If any of the following side effects occur while taking ranibizumab ophthalmic, check with your doctor or nurse immediately:

More common:
  • Blindness
  • bloody eye
  • blurred vision or loss of vision
  • decreased vision or other changes in vision
  • disturbed color perception
  • dizziness
  • double vision
  • dry eye
  • eye pain
  • fainting
  • feeling of having something in the eye
  • halos around lights
  • headache
  • night blindness
  • overbright appearance of lights
  • pain or tenderness around the eyes and cheekbones
  • red, sore eyes
  • redness of the white part of the eyes or inside of the eyelids
  • redness, swelling, or itching of the eyelid
  • seeing flashes or sparks of light
  • seeing floating spots before the eyes, or a veil or curtain appearing across part of vision
  • sensitivity of the eye to light
  • tearing of the eyes
  • tunnel vision
  • watering of the eyes
Less common:
  • Body aches or pain
  • chest pain
  • chills
  • cough
  • difficulty with breathing
  • dry mouth
  • fainting
  • fast, slow, or irregular heartbeat
  • general feeling of discomfort or illness
  • head congestion
  • hoarseness, loss of voice, or other voice changes
  • loss of consciousness
  • muscle aches and pains
  • nasal congestion
  • pain in the chest, groin, or legs, especially the calves
  • painful blisters on the trunk of the body
  • pale skin
  • runny nose
  • severe, sudden headache
  • shivering
  • slurred speech
  • sneezing
  • sore throat
  • sudden loss of coordination
  • sudden, severe weakness or numbness in the arm or leg
  • sudden, unexplained shortness of breath
  • sweating
  • tightness in the chest
  • trouble sleeping
  • unexplained weight loss
  • unusual tiredness or weakness

Minor Side Effects

Some ranibizumab ophthalmic side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:

More common:
  • Back pain
  • difficulty having a bowel movement (stool)
  • difficulty with moving
  • muscle stiffness
  • swelling or redness in the joints

For Healthcare Professionals

Applies to ranibizumab ophthalmic: intravitreal solution


-Very common (10% or more): Conjunctival hemorrhage (up to 74%), eye pain (up to 35%), vitreous floaters (up to 27%), increased intraocular pressure (up to 24%), vitreous detachment (up to 21%), intraocular inflammation (up to 18%), vision disturbance/blurred vision (up to 18%), cataract (up to 17%), foreign body sensation in eyes (up to 16%), eye irritation (up to 15%), increased lacrimation (up to 14%), blepharitis (up to 12%), dry eye (up to 12%), eye pruritus (up to 12%), ocular hyperemia (up to 11%), maculopathy (up to 11%), retinal disorder (10%), vitreitis, retinal hemorrhage
-Common (1% to 10%): Retinal degeneration, retinal detachment, retinal tear, retinal pigment epithelium detachment, retinal pigment epithelium tear, reduced visual acuity, vitreous hemorrhage, vitreous disorder, uveitis, iritis, iridocyclitis, subcapsular cataract, punctuate keratitis, corneal abrasion, anterior chamber flare, eye hemorrhage, conjunctivitis, allergic conjunctivitis, eye discharge, photopsia, photophobia, ocular discomfort, eyelid edema, eyelid pain, conjunctival hyperemia, posterior capsule opacification, endophthalmitis, injection site hemorrhage
-Uncommon (0.1% to 1%): Blindness, endophthalmitis, hypopyon, hyphema, keratopathy, iris adhesion, corneal deposits, corneal edema, corneal striae, injection site pain, injection site irritation, abnormal sensation in eye, eyelid irritation[Ref]


Very common (10% or more): Nasopharyngitis (up to 16%), bronchitis (up to 11%)
Common (1% to 10%): Cough, upper respiratory tract infection, sinusitis, chronic obstructive pulmonary disease[Ref]

Nervous system

Very common (10% or more): Headache (up to 12%)
Common (1% to 10%): Peripheral neuropathy, stroke[Ref]


Very common (10% or more): Anemia (up to 11%)[Ref]


Very common (10% or more): Arthralgia (up to 11%)[Ref]


Very common (10% or more): Arterial thromboembolic events (up to 10.8%)
Common (1% to 10%): Peripheral edema, atrial fibrillation[Ref]


Very common (10% or more): Nausea (up to 10%)
Common (1% to 10%): Constipation, gastroesophageal reflux disease[Ref]


Common (1% to 10%): Urinary tract infection[Ref]


Common (1% to 10%): Hypersensitivity reactions[Ref]


Common (1% to 10%): Immunoreactivity, seasonal allergy, allergic reactions (rash, urticaria, pruritus, erythema)[Ref]


Common (1% to 10%): Hypercholesterolemia[Ref]


Common (1% to 10%): Influenza, would healing complications, fatal events
Frequency not reported: Non-ocular hemorrhage[Ref]


Common (1% to 10%): Anxiety[Ref]


Common (1% to 10%): Renal failure, chronic renal failure[Ref]


1. "Product Information. Lucentis (ranibizumab ophthalmic)." Genentech, South San Francisco, CA.

2. Cerner Multum, Inc. "Australian Product Information." O 0

3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

It is possible that some side effects of ranibizumab ophthalmic may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.